A prospective evaluation demonstrates that a CRISPR-Cas13a assay targeting cell-free bacterial DNA in pleural effusion supernatant achieves 80.5 percent diagnostic sensitivity for tuberculous pleurisy.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.